Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
56 hedge funds and large institutions have $1.02M invested in Navidea Biopharmaceuticals Inc. in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 7 closing their positions.
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
6% more funds holding
Funds holding: 53 → 56 (+3)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
74% less capital invested
Capital invested by funds: $3.91M → $1.02M (-$2.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$13.1K |
| 2 |
CAG
Csenge Advisory Group
Clearwater,
Florida
|
+$8.24K |
| 3 |
Millennium Management
New York
|
+$4.04K |
| 4 |
SS
Simplicity Solutions
Minneapolis,
Minnesota
|
+$3.13K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$2.58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWM
Cornerstone Wealth Management
St. Peters,
Missouri
|
-$1.13M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$282K |
| 3 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$180K |
| 4 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
-$55K |
| 5 |
Goldman Sachs
New York
|
-$31K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SFS
51
Sowell Financial Services
North Little Rock,
Arkansas
| – | -$55K | -12,020 | Closed |
|
|
52
Goldman Sachs
New York
| – | -$31K | -6,701 | Closed |
|
|
BCM
53
Bridgeway Capital Management
Houston,
Texas
| – | -$20K | -4,275 | Closed |
|
|
CPIG
54
Chicago Partners Investment Group
Chicago,
Illinois
| – | -$1K | -174 | Closed |
|
|
CWM
55
Cornerstone Wealth Management
St. Peters,
Missouri
| – | -$1.13M | -25 | Closed |
|
|
LTFS
56
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | +$25 | +6 | New |
|
|
AIC
57
Ameritas Investment Company
Lincoln,
Nebraska
| – | +$206 | +50 | New |
|
NAVB Hedge Fund Activity: Q4 2018 in Review
56 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q4 2018, worth a combined $1.02M — down 74% from $3.91M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new NAVB positions and 7 closed out — a net gain of 3 holders — while 6 added to existing stakes and 7 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $13.1K. The largest seller was Cornerstone Wealth Management, exiting entirely with an estimated $1.13M sold.
- 56 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q4 2018, up from 53 in Q3 2018.
- Funds reported $1.02M of Navidea Biopharmaceuticals Inc. stock for Q4 2018, down 74% quarter-over-quarter.
- 10 funds opened new Navidea Biopharmaceuticals Inc. positions in Q4 2018 and 7 closed out, a net change of +3 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q4 2018 was Two Sigma Securities, an estimated $13.1K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q4 2018 was Cornerstone Wealth Management, an estimated $1.13M sold.
Based on aggregated 13F filings for Q4 2018.